

Bidang Kesehatan dan Ilmu
Keperawatan

**LAPORAN HASIL PENELITIAN
HIBAH PENELITIAN TIM PASCASARJANA-HPTP
(HIBAH PASCA)**



Eksplorasi Karakter Molekul Inhibin B Hasil Isolasi Dari Kultur Sel Sertoli *Rattus norvegicus*: Upaya Pengembangan Kontrasepsi berbasis Hormonal Peptida Pada Pria

Oleh:

**Prof. Dr. Aulanni'am, drh., DES.
Dr. Ir. Gatot Ciptadi, DESS.
Dr. Ir. Chanif Mahdi, MS.**

Dibiayai Oleh Direktorat Jenderal Pendidikan Tinggi, Departemen Pendidikan Nasional,
Melalui DIPA Universitas Brawijaya Nomor : 0174.0/023-04.2/XV/2009, tanggal 31
Desember 2008 dan Berdasarkan SK Rektor Nomor : 147/SK/2009, tanggal 30 April
2009

**UNIVERSITAS BRAWIJAYA
MALANG
2009**

**HALAMAN PENGESAHAN
LAPORAN TAHUNAN HIBAH PASCA**

1. Judul Penelitian : Eksplorasi Karakter Molekul Inhibin B Hasil Isolasi Dari Kultur Sel Sertoli *Rattus norvegicus*: Upaya Pengembangan Kontrasepsi berbasis Hormonal Peptida Pada Pria
2. Peneliti Utama
- a. Nama Lengkap : Prof. Dr. Aulanni'am, drh.,DES.
 - b. Jenis Kelamin : P
 - c. NIP : 19600903 198802 2 001
 - d. Jabatan Fungsional : Guru Besar Madya
 - e. Jabatan Struktural : Wakil Ketua I Program Kedokteran Hewan Universitas Brawijaya
 - f. Bidang Keahlian : Biokimia
 - g. Program Studi/Jurusan : Kimia

3. Daftar Anggota Peneliti dan Mahasiswa:


No.	NAMA	BIDANG KEAHLIAN	FAKULTAS JURUSAN	PERGURUAN TINGGI
1.	Dr. Ir. Gatot Ciptadi, DESS.	Kultur Sel	Peternakan	Univ. Brawijaya
2.	Dr. Ir. Chanif Mahdi, MS.	Biokimia Kedokteran	MIPA	Univ. Brawijaya
3.	Muslim Akmal	-	S3 Ilmu Kedokteran	Fak. Kedokteran Univ. Brawijaya
4.	Muhammad Hilman Fu'adil Amin	-	S2 Biologi	FMIPA Univ. Brawijaya
5.	Puspitaningrum	-	S2 Kimia	FMIPA Univ. Brawijaya
6.	Analis Wisnu Wardhana	-	S2 Biomedik	Fak. Kedokteran Univ. Brawijaya

4. Pendanaan dan jangka waktu penelitian

- a. Jangka waktu penelitian yang diusulkan : 3 tahun
- b. Jangka waktu penelitian yang sudah dijalani : 1 tahun
- c. Biaya total yang diusulkan : Rp. 241.000.000,-
- d. Biaya yang disetujui tahun I : Rp. 75.000.000,-

Mengetahui,
Dekan Fakultas MIPA
Universitas Brawijaya

Prof. Dr. Drs. Marjono, M.Phil.
NIP. 19621116 198803 1 004



Malang, 16 Nopember 2009
Peneliti Utama,

Prof. Dr. Aulanni'am, drh.,DES.
NIP. 19600903 198802 2 001

Menyetujui,
Ketua Lembaga Penelitian dan Pengabdian Kepada Masyarakat
Universitas Brawijaya



Prof. Dr. Ir. Siti Chuzaemi, MS
NIP. 19530414 198002 2 001

ABSTRACT

The purpose of this study is to isolate, identify, and characterize the inhibin B protein of *Rattus norvegicus* Sertoli cell culture. In this research, culture of Sertoli cell using by DMEM medium + FCS 15%. Confirmation of inhibin B protein from Sertoli cell culture by dot blot technique used inhibin B polyclonal antibody. Identification and characterization of inhibin B protein from Sertoli cell culture by SDS PAGE. The result of this studies showed that Sertoli cell culture is the source of inhibin B protein with molecular weight of 175, 163, 153, 81, 78, 66, dan 29 kDa.

Key words: Inhibin B, male hormonal contraception

RINGKASAN

Sungguh tidak dapat dipungkiri bahwa pertumbuhan penduduk di dunia dewasa ini meningkat secara drastis dan fantastis. Sebagai negara yang sedang berkembang, fenomena ini nampaknya juga dialami oleh Indonesia dimana terdapat adanya kecenderungan peningkatan pertumbuhan penduduk dari tahun ke tahun. Apabila hal ini tidak diantisipasi, maka dikhawatirkan akan terjadi ledakan penduduk (*baby boom*) di dunia maupun Indonesia dengan berbagai dampaknya. Program keluarga Berencana (KB) yang pernah dicanangkan oleh pemerintah ternyata belum mampu menekan pertumbuhan penduduk yang terus mengkhawatirkan. Salah satu faktor yang menyebabkan kegagalan program KB adalah rendahnya apresiasi dan partisipasi pria untuk menggunakan kontrasepsi.

Untuk menanggulangi hal ini, diperlukan upaya-upaya yang konsisten, kontinu, terarah, terukur, dan sistematis untuk menemukan kandidat-kandidat baru kontrasepsi khususnya kontrasepsi hormonal pada pria. Saat ini, dibeberapa belahan dunia (Eropa, Amerika, Afrika, China, dan India) terus diujikembangkan kandidat-kandidat kontrasepsi hormonal pria baru yang aman, efektif, praktis, dan akseptabel.

Penelitian yang diusulkan ini direncanakan akan dilaksanakan selama 3 (tiga) tahun. Penelitian pada **tahun pertama (sudah dijalankan)** difokuskan pada produksi isolat inhibin B melalui serangkaian proses yang dimulai dari isolasi, karakterisasi dan purifikasi, pengukuran kandungan protein, glikoprotein dan karbohidrat, dan pengukuran kadar isolat inhibin B. Pada **tahun kedua** penelitian akan dilanjutkan dengan uji potensi isolat inhibin B yang didapat pada tahun I sebagai kandidat kontrasepsi berbasis hormonal peptida pada pria. Uji ini akan dilakukan secara *invivo* dengan menggunakan hewan coba *Rattus norvegicus* dengan mengukur variabel: motilitas, konsentrasi, dan persentase spermatozoa yang hidup. Selain itu, juga diukur kadar serum inhibin B, FSH, LH, dan testosteron. Sedangkan pada **tahun ketiga**, akan dilakukan uji potensi isolat inhibin B sebagai kandidat kontrasepsi berbasis hormonal peptida pada pria dengan melakukan uji fertilisasi baik secara *invitro* maupun *invivo* dengan menggunakan *Rattus norvegicus* sebagai hewan coba.

DAFTAR PUSTAKA

- Akmal, M., Aulanni'am., Rasmaidar., Dasrul., T.N. Siregar dan E. Rahmi. 2008. Efek dekok biji pinang (*Areca catechu*) terhadap motilitas spermatozoa tikus (*Rattus norvegicus*): upaya menemukan kandidat antifertilitas pria. *Jurnal Kedokteran Hewan* 2(2):20-24.
- Allenby, G., P.M. Foster and. R.M. Sharpe. 1991. Evidence that Secretion of Immunoactive Inhibin by Seminiferous Tubules From the Adult Rats Testis is Regulated by Specific Germ Cell Types: Correlation Between *in Vivo* and *in Vitro* Studies. *Endocrinology*, 128:467-476.
- Amory, J.K. And W.J. Bremner. 2005. Oral testosterone in oil plus dutasteride: a pharmacokinetic study in men. *J Clin Endocrinol Metab* 90:2610-2617.
- Amory, J.K., S.T. Page and W.J. Bremner. 2005. Drug insight: recent advances in male hormonal contraception. *Nature clinical practice endocrinology & Metabolism*: 1-16.
- Anawalt, B.D., R.A. Bebb., A.M. Matsumoto., N.P. Groome., P.J. Illingworth., A.S. McNeilley and W.J. Bremmer. 1996. Serum Inhibin B Levels Reflect Sertoli Cell In Normal Men And Men With Testicular Dysfunction. *J. Clin. Endocrinol, Metab*, 81:3341-3345.
- Anawalt, B.D. and J.K. Amory (2001). Advances in male hormonal contracetion. *Ann Med*, 33(9):587-595.
- Anawalt, B.D. et al. 2005. Very low-dosage oral levonogestrel plus intramuscular testosteron enanthate suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. *J. Androl*, 26:720-727.
- Anderson, R.A., D.S. Irvine., C. Balfour., N.P Groome and S.C. Riley. 1998. Inhibin B in seminal plasma: testicular origin and relationship to spermatogenesis. *Human Reproduction*, 13:920-926.
- Anderrson, A.M. 2000. Inhibin B in the assessment of seminiferous tubular function. *Clinical Endocrinology & Metabolism*, 14(3):389-397.
- Anderson, R..A. 2000. Prospects for hormonal contraception in the male. *Redproductive Medicine Review*, 8:127-142.
- Anderson, R.A. and R.M. Shape. 2001. Regulation of Inhibin production in the Human Male and Its Clinical Applications. *Int J. Androl*, 23:136-144.
- Anderson, R.A. and D.T. Baird. 2002. Male Contraception. *Endocrine Reviews*, 23(6):735-762.
- Anonymous, 2000. Male hormonal contraception: a safe, acceptable and reversible choice. *MJA* (172):254-255.
- Bagatell, C.J., J.R. Heiman., A.M.Matsumoto., J.E. Rivier and W.J. Bremner. 1994. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. *J. Clin Endocrinol Metab*, 79:561-567.
- Baird, D.T. and A.F. Glasier. 2007. Science, medicine, and the future: contraception. <http://bmj.com/cgi/content/full/319/7215/969#BIBL>.
- Bame, J.H., J.C. Dalton., S.D. Degelos., et al. 1999. Effect Of Long-Term Immunization Against Inhibin On Sperm Output In Bulls. *Biol Reprod*. 60:1360-1366.

- Barfield, A., J. Melo., E. Coutinho., F. Alvarez-Sanchez., A. Faudes., V. Brache., P. Leon., J. Frich., G. Barisch., W. Weiske., P. Bremner., D. Mishell., G. Bernstein and A. Ortiz. 1977. Pregnancies associated with sperm concentration below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. *Contraception*, 20:121-127.
- Bebb, R.A., D. Anawalt. And R.B. Christensen. 1996. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. *J. Clin Endocrinol Metab*, 81:757-762.
- Behre, H.M., K. Abshagen., M. Oettel., D. Hubber and E. Nieschlag. 1999. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. *Hum Reprod* 16: 2570-2577.
- Brady, D.M., J.K. Amory., A. Perheentupa., M. Zitzmann., C.J. Hay., D. Apter., R.A. Anderson., W.J. Bremner., P. Pollanen., E. Nieschlag., F.C. Wu and W.M. Kersemaekers. 2006. A multi-center study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. *Hum Reprod*, in press.
- Brooks, A.N. 1998. Comparative Physiology Of The Reproductive Endocrine System In Laboratory Rodents And Human. *Pure & Appl. Chem*, 70(9): 1633-1646.
- Büchter, D., S. von Eckardstein., A. von Eckardstein., A. Kamischke., M. Simoni., H.M. Behre. 1999. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. *J Clin Endocrinol Metab*, 84:1244-1249.
- Chada, M., R. Prusa., J. Bronsky., K. Kotaska., K. K. Sidlova., M. Pechova and L. Lisa. 2003. Inhibin B, follicle stimulating hormone, luteinizing hormone and testosterone during childhood and puberty in males: changes in serum concentration in relation to age and stage of puberty. *Physiol. Res*, 52:45-51.
- Chen, J., D.J. Hwang., C.E. Bohl., D.D. Miller and J.T. Dalton. 2005. A Selective Androgen Receptor Modulator for Hormonal Male Contraception. *The journal of Pharmacology and Experimental Therapeutics*, 312:546-553.
- Cho, N. *et al.* 1998. Discovery of a novel, potent and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH). *Receptor. J. Med Chem*, 41:4190-4195.
- Crosignani, P.G. 2002. Hormonal contraception: what is new?. *Human Reproduction Update*, 8(4):359-371.
- Coert, A *et al.* 1975. The pharmacology and metabolism of testosterone undecanoate (tu), a new orally active androgen. *Acta Endocrinol (Copenh)* 79:789-800.
- De Kretser, D.M. and J.R. McFarlane. 1996. Inhibin In The Male. *J. Androl*, 17: 179-182.
- De Kretser, D.M., A. Meinhardt., T. Meehan., D.J. Phillips., M.K. O'Bryan and K.A. Loveland. 2000. The Roles of Inhibin and Related Peptides in Gonadal Function. *Mol Cell Endocrinol*, 161:43-46.
- Depuydt, C.E., A.M. Mahmoud., W.S. Dhooge., F.A. Schoonjans and F.H. Comhaire. 1999. Hormonal regulation of inhibin B secretion by immature rat Sertoli cells in vitro: possible use as a bioassay for estrogen detection. *Journal of Andrology*, 20(1):54-62.

Fauzi, A., M. Lucianawaty., L. Hanifah dan N. Bernadette. (2005). Penduduk Indonesia 2025 Akan Capai 273,65 Juta Jiwa. <http://situs.kesrepro.info/info/agu/2005/info02.htm>.

Forest, C., A. Bettella., D. Spolaore., M. Merico., M. Rossato and A. Ferlin. 1999. Supression of the High Endogenous Levels of Plasma FSH in Infertile Men are Associated with Improved Sertoli Cell Function as Reflected by Elevated Levels of Plasma Inhibin B. *Human Reproduction*, 19(6):1431-1437.

Forest, C.A., A. Betella., M. Merico., A. Garolla., M. Plebani., A. Ferlin and M. Rossato. 2004. FSH in the treatment of oligozoospermia. *Mol Cell Endocrinol*, 161:89-97.

Fotherby K et al. 1972. Effect of low doses of synthetic progestagens on testicular function. *Int J Fertil* 17:113-119.

Gonzalo, I.T., R.S. Swerdloff., A.L. Nelson., B. Clevenger., R. Garcia., N. Berman and C. Wang. 2002. Levonorgestrel implants (Norplant II) for male contraception clinicals trials: combination with transdermal and injectable testosterone. *J Clin Endocrinol Metab*, 87:3562-3572.

Grimes, D.A., L.M. Lopez., M .F. Gallo., V. Halpern., K. Nanda and K.F. Schulz. 2006. Steroid hormones for contraception in men. *The cochrane library* (issn 1464-780x).

Gu, Y.Q., J.S. Tong., D.Z. Ma., X.H. Wang., D. Yuan., W.H. Tang and W.J. Bremner. 2004. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. *J. Clin Endocrinol Metab*, 88:562-568.

Guy, Y.L. et al. 2004. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men. *J Androl*, 25:720-727.

Hair, W.M, K. Kitteridge., D.B. O'Connor and F.C.W. Wu. 2001. A novel male contraceptive pill-patch combination : oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. *J Clin Endocrinol Metab*, 86:5201-5209.

Handelsman, D.J., J.A. Spaliviero and A.F. Phippard. 1990. Highly vectorial secretion of inhibin by primate Sertoli cells in vitro. *Journal of Clinical Endocrinology and Metabolism*, 71:1235-1238.

Handelsman, 1995. Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. *Fertil Steril*, 63:125-133.

Handelsman, 2003. Hormonal contraception-lessons from the East when the Western market fails. *Journal of Clin Endocrinol and Metab*, 88:559-561.

Hay, C.J., B.M. Brady., M. Zitzmann., K. Osmanagaoglu., P. Pollanen., D. Apter., F.C. Wu., R.A. Anderson., E. Nieschlag., P. Devroey., I. Huhtaniemi and W.M. Kersemakers. 2005. A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. *J Clin Endocrinol Metab*, 90:2042-2049.

Hayes, F. J., S. DeCruz, S.B. Seminara., P.A. Boepple and W.F. Crowley Jr. 2001. Differential Regulation of Gonadotropin Secretion by Testosterone in the Human Male: absence of a Negative Feedback Effect of Testosterone on Follicle Stimulation Hormone Secretion. *J. Clin Endocrinol Metab*, 86:53-58.

Heckel, M.J. 1939. Production of oligospermia in a man by the use of testosterone propionate. *Proc Soc Exp Biol Med*, 40:658-659.

- Herbst, K.L., B.D. Anawalt., J.K. Amory and W.J. Bremner. 2004. Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist.. *J Clin Endocrinol Metab*, 87:3215-3220.
- Illingworth, P.J., N.P. Groome., W. Byrd *et al.* 1996. Inhibin-B: A Likely Candidate For The Physiologically Important Form Of Inhibin In Men. *J. Clin. Endocrinol. Metab*, 81:1321-1325.
- Jensen, T.K., A.M. Anderson. and N.H. Hjollund *et al.* 1998. Inhibin B as a Marker Spermatogenesis: Correlation to Differences in Sperm Concentration and Follicle-Stimulating Hormone Levels. A Study of 349 Danish Men. *J. Clin. Endocrinol. Metab*, 82:4059-4063.
- Johnson, M. H. and B. J. Everitt. 2000. Essential Reproduction. 5th ed. Blackwell Science Ltd.
- Junaidi A *et al.* 2005. Norethisterone enanthate has neither a direct effect on the testis nor on the epididymis: a study in adult male cynomolgus monkeys (*Macaca fascicularis*). *Eur J Endocrinol*, 152:655-661.
- Kamischke, A., S. Venhern., D. Ploger., S. Von Eckardstein and E. Nieschlag. 2000. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. *Clinical Endocrinol*, 53:43-52.
- Kamischke A., S. Venhern., D. Ploger., S. von Eckardstein and E. Nieschlag. 2001. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. *J Endocrinol Metab* 86:303-309.
- Kamischke A., T. Heuermann., K. Kruger., S. S. von Eckardstein., I. Schellschmidt., A. Rubig and E. Nieschlag. 2002. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. *J Clin Endocrinol Metab*, 87:530-539.
- Kamischke, A and Nieschlag. 2004. Progress towards hormonal male contraception. *Trends Pharmacol Sci*, 25:49-57.
- Kaneko, H., M. Matsuzaki., J. Noguchi., K. Kikuchi., K. Ohnum., and M. Ozawa. 2006. Changes in circulating and testicular levels of inhibin A and B during postnatal development in bulls. *Journal of Reproduction and Development*, 52(6):741-749.
- Kangasniemi, M., A. Kaipia, J. Toppari., A. Perheentupa., I. Huhtaniemi and M. Parvinen. 1990. Cellular Regulation of Follicle-Stimulating Hormone (FSH) Binding in Rat Seminiferous Tubules. *J. Androl*, 11:36-343.
- Kinniburgh, D., H. Zhu., I. Cheng., A.T. Kicman., D.T. Baird and R.A. Anderson. 2002. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. *Hum Reprod*, 17:2869-2877.
- Klingmuller, D and G. Haidl. 1997. Inhibin B In Men With Normal And Disturbed Spermatogenesis. *Hum. Reprod*, 12:2376-2378.
- Liefke, E., M. Simoni., A. Kamischke., *et al.* 1997. Does The Gonadotropic Axis Play A Role In The Pathogenesis Of Sertoli-Cell-Only Syndrome? *Int.J.Androl*, 20:29-36.
- Liu, P.Y., R.S. Swedloff., B.D. Anawalt., R.A. Anderson., W.J. Bremner., J. Elliesen., Yi-Qun Gu., W.M. Kersemaekers., R.I. McLachlan., M.C. Merigliola., E. Nieschag., R. Sitruk-Ware., K. Vogelsong., Xing-Hai Wang., F.C.W. Wu., M. Zitzmann., D.J. Handelsman and C. Wang. 2008. Determinants of the rate and

- extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. *J Clin Endocrinol Metab*, 93:1774-1783.
- Lockwood, G.M., S. Muttukhrisna and W.L. Ledger. 1998. Inhibins and activin in human ovulation, conception, and pregnancy. *Human reproduction Update*, 4(3):284-295.
- Luisi, S., P. Florio., F.M. Reis and F. Petraglia. 2005. inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy. *Human Reproduction Update*, 11(2):123-135.
- Marchetti, C., M. Hamdane., V. Mitchell., K. Mayo., L. Devisme., J.M. Rigot., J.C. Beauvillain., E. Hermand and A. Defossez. 2003. *Biology of Reproduction*, 68:230-235.
- Martin, C.W., R.A. Anderson., L. Cheng., P.C. Ho., Z. van der Spuy., K.B. Smith., A.F. Glasier., D. Everington and D.T. Baird. 2000. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. *Hum. Reprod*, 15:637-645.
- Mather, J.P., K.M. Attie., T.K Woodruff., G.C. Rice and D.M. Phillips. 1992. Activin stimulates spermatogonial proliferations in germ-cell cocultures from immature rat testis. *Endocrinology*, 127:3206-3214.
- Mather, J.P., and L.A. Krummen. 1992. Inhibin, activin, and growth factors: paracrine regulators of testicular function. In: Spermatogenesis-Fertilization-Contraception: Molecular, Cellular, and endocrine events in male Reproduction, edited by E. Nieschlag abd U-F Habenicht, pp 169-200, Springer-Verlag, New York.
- Matsumoto, A.M. (1989). Hormonal Control of Human Spermatogenesis. In Burger H and de Kretser D (eds), The Testis. Raven Press, New York, pp, 181-196.
- Matthiesson, K.L., J.K. Amory., R. Berger., A. Ugoni, R.I. McLachlan, and W.J. Bremner. 2005. Novel male hormonal contraceptive combinations : the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5- α -reductase inhibitor or GnRH antagonist. *J Clin Endocrinol Metab*, 90:91-97.
- McNeilly, A.S., C.J.H. Souza., D.T. Baird., I.A. Swanston., J. McVerry., J. Crawford., M. Cranfield and G.A. Lincoln. 2002. Production of inhibin A not B in rams: changes in plasma inhibin A during testis growth and expression of inhibin/activin subunit mRNA and protein in adults testis. *Reproduction*, 123:827-835.
- Meriggiola, M.C., S. Marcovina., C.A. Paulsen and W.J. Bremner. 1995. Testosterone enanthate at the dose 200 mg/week decreases HDL-cholesterol levels in healthy men. *Int J Androl*, 18:237-242.
- Meriggiola, M.C., W.J. Bremner., C.A. Paulsen., A. Valdiserri., L. Incorvaia., R. Motta., A. Pavani., M. Capelli and C. Flamigni. 1996. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. *J Clin Endocrinol Metab*, 81:3018-3023.
- Meriggiola, M.C., W.J. Bremner., A. Constantino., A. Pavani., M. Capelli and C. Flamigni. 1997. An oral regimen of cyproterone acetate and testosterone for spermatogenic suppression in men. *Fertil Steril*, 68: 844-850.
- Meriggiola, M.C., A. Constantino., W.J. Bremner and A.M. Morselli-Labate. 2002. Twenty-one day administration of dienogest reversibly suppress gonadotropins and testosterone in normal men. *J. Clin Endocrinol Metab*, 87: 2107-2113.

- Muttukhrisna, S., A. Farouk., S. Sharma., L. Evans., N. Groome., W. Ledger and M. Sathanandan. 2001. Serum activin A and follistatin in disorders of spermatogenesis in men. *European Journal of Endocrinology*, 144:425-429
- Nieschlag E., H.M. Behre., U. Engelmann and U. Schwarzer. 1996. Male contribution to contraception: in nieschlag e, behre hm (eds): andrology: male reproductive health and dysfunction. *Heidelberg Springer*, pp 399-418.
- Nieschlag E., H.M. Behre., U. Engelmann and U. Schwarzer. 2000. Male contribution to contraception: in nieschlag e, behre hm (eds): andrology: male reproductive health and dysfunction. *Heidelberg Springer*, pp 399-418.
- Nowroozi, M.R., K. Radkah., M. Ayati., H. Jamshidian., A. Ranjbaran and P. Jabalameli. 2008. Serum inhibin B concentration as a prognostic factor for prediction of sperm retrieval in testis biopsy of patients with azoospermia. *Arch Iranian Med*, 11(1):54-56.
- Page, S.T., J.K. Amory and W.J. Bremner. 2008. Advances in male contraception. *Endocrine Revies*, 29(4):465-493.
- Pangkahila, 2007. Program KB cegah *unsafe abortion*, dikalangan masyarakat miskin. <http://www.waspada.co.id>.
- Partodihardjo, 1992. Ilmu Reproduksi Hewan. Cetakan ketiga. Mutiara Sumber Widya. Jakarta. Hal. 522-556.
- Pavlou, S.N., K. Brewer., M.G. Farley., J. Lindner., M.C. Bastias., B.J. Rogers., L.L. Swift., J.E. Rivier., W.W. Vale and P.M. Conn. 1991. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. *J Clin Endocrinol Metab*, 73:1360-1369.
- Pierik, F.H., J.T.M. Vreeburg., T. Stijnen. et al. 1998. Serum Inhibin B As A Marker Of Spermatogenesis. *J. Clin. Endocrinol. Metab*, 83:3110-3114.
- Raleigh, V.S. 1999. Trends in world population: how will the millennium compare with the past? *Hum Reprod Update* 5:500.
- Ramaswamy, S and T.M. Plant. 2001. Operation of the Follicle-Stimulating Hormone (FSH)-inhibin B Feedback Loop in the Control of Primate Spermatogenesis. *Mol Cell Endocrinol*, 180:93-101.
- Rannikki, A.S., F.P. Zhang and I.T. Huhtaniemi. 1995. Ontogeny of Follicle-Stimulating Hormone Receptor Gene Expression in The Rat Testis and Ovary. *Mol Cell Endocrinol*, 107:199-208.
- Robert, K and A. Peter. 1993. Harper's Biochemistry, 23rd edition, Preble Hall International, inc., USA.
- Robertson, D.M., T. Stephenson and R.I. McLachlan. 2003. Characterization of plasma inhibin forms in fertile and infertile men. *Human Reproduction*, 18(5):1047-1054.
- Roberts, V., H. Meunier., P.E. Sawchenko dan W. Pale. 1989. Differential production and regulation of inhibin subunits in rat testicular cell types. *Endocrinology*, 125:2350-2359.
- Rombauts, L., D. Vanmontfort., G. Verhoeven and E. Decuypere. 1992. Immunoreactive inhibin in Plasma, Amniotic Fluid, and Gonadal Tissue of Male and Female Chick Embryos. *Biology Reproduction*, 46:1211-1216.
- Rosen, J and A. Negro-Vilar. 2002. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolitic activity in bone and muscle and improved safety profile. *J Musculoskelet Neuronal Interact* 2:222-224.

- Schanbacher, B.D. 1991. Pituitary And Testicular Responses Of Beef Bulls To Active Immunization Against Inhibin Alpha. *J. Anim Sci*, 69:252-257.
- Schearer, S.B., F. Alvarez-Sanchez., J. Anselmo., P. Bremner., E. Coutinho., A. Latham-Faunoles., J. Frick., B. Heinild and E.D.B. Johansson. 1978. Hormonal contraception for men. *Int J Androl*, 2:680-695.
- ScienceDaily. 2006. Hormonal Male Contraception Reversibel After Few Months for All Men. <http://www.Male%20hormonal-1\Male-10-mht>.
- Sharpe, R.M. 1989. Follicle-stimulating Hormone and Spermatogenesis in the Adult Male. *J. Endocrinol*, 57:152-159.
- Sipilä, P., J. Jalkanen., I.T. Huhtaniemi and M. Poutanen. 2009. Novel epididymal proteins as a target for the development of post-testicular male contraception. *Reproduction*, 137:379-389.
- Sjogren, B and C. Gottlieb. 2001. Testosterone for male contraception during one year: attitudes, well-being and quality of sex life. *Contraception*, 64:59-65.
- Steel, R.G.D. and Torrie. 1993. Prinsip dan Prosedure Statistika: Suatu Pendekatan Biometrik. Edisi II. PT. Gramedia Pustaka Utama, Jakarta.
- Steidle, C et al. 2003. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. *J Clin Endocrinol Metab*, 88:2673-2681.
- Tierney, M.L., N.H. Goss., S.M. Tomkins., D.B. Kerr., D.E. Pitt., R.G. Forage., D.M Robertson., M.T.W. Hearn and D.M. de Kretser. 1990. Physicochemical And Biological Characterization Of Recombinant Human Inhibin A. *J. Endocrinology*, 127:2398-2946.
- Tilbrook, A.J. and I.J. Clarke. 2001. Negative Feedback Regulation of the Secretion and Actions of Gonadotropin-Releasing Hormone in Males. *Biol Reprod*, 64:735-752.
- Toelihere, M.R. 1985. Fisiologi Reproduksi Pada Ternak. 6th ed. Penerbit Angkasa, Bandung.
- Tom, L., S. Bhushan., W. Salameh., B. Steiner., M. Peterson., R.Z. Sokol., J. River and W. Pale. 1992. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone and testosterone enanthate. *J.Clin Endocrinol Metab*, 75:476-483.
- Tomera, K. et al. 2001. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonist leuprorelin or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. *J Urol*, 165:1585-1589.
- Trussel, J and K. Kost. 1987. Contraceptive failure in the United States: a critical review of the literature. *Study Fam Plann*, 18:237-283.
- Turner, L. 2003. Contraceptive efficacy of a depot progestin and androgen combination in men. *J Clin Endocrinol Metab*, 88:4659-4667.
- United Nations Population Division. 2000. World population prospects: The 2000 revision. New York, United Nations.
- Von Eckardstein, S., M. Simoni., M. Bergmann. et al. 1999. Serum Inhibin B In Combinaton With Serum Follicle Stimulating Hormone (FSH) Is A More Sensitive Marker Than Serum Fsh Alone For Impaired Spermatogenesis In Men, But Cannot Predict The Presence Of Sperm In Testicular Tissue Samples. *J. Clin. Endocrinol. Metab*, 84:2496-2501.

- Van Dissel-Emiliani, F.M., A.J. Grootenhuis., F.H. de Jong and D.G. de Rooij. 1989. Inhibin reduces spermatogonial numbers in testes of adult mice and Chinese hamster. *Endocrinology*, 125: 1-4.
- Wallace., E.M., R.J. Aitken and F.C.W. Wu. 1992. Residual sperm function in oligozoospermia induced by testosterone enanthate administered as a potential male contraceptive. *Int J Androl*, 15:416-424.
- Walker, J.M. 1994. Basic Protein and Peptide Protocols. Humana Press. Totowa, New Jersey pp 381-382.
- Winters, S.J., C. Wang., E. Abdelrahman., V. Hadeed., M.A. Dyky and A. Brufsky. 2006. Inhibin B Levels in Healthy Young Adult Men and Prepubertal Boys: Is obesity the Cause for the Contemporary Decline in Sperm Count Because of Fewer Sertoli Cells? *Journal of Andrology*, 27(4):560-564.
- World Health Organization, (1990). Task force on methods for the regulation of male fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. *Lancet*, 335, 955.
- World Health Organization, (1996). Task force on methods for the regulation of male fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. *Fertil steril*, 65:821-829.
- World Health Organization, (1998). Task force on post-ovulatory methods for fertility regulation. Randomised and controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. *Lancet*, 352:428-433.
- World Health Organization, (2000). Department of Reproductive Health and Research, Annual Technical Report, World Health Organization, Geneva, Switzerland.
- World Health Organization, (2003). Who Laboratory manual for the examination of human semen and sperm-cervical mucus interaction : Cambridge University Press.
- Wu, F.C., R. Balasubramanian., T.M. Mulders and H.J. Coelingh-Bennink. 1999. Oral progesterone combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. *J Clin Endocrinol Metab*, 84:112-122.
- Zhang, G.Y. et al. 1998. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. *J Androl*, 19:761-768.
- Zhang, G.Y., Y.Q. Gu., X.H. Wang., Y.G. Cui. And W.J. Bremner. 1999. A clinical trial of injectable testosterone undecanoate for contraception in Chinese men. *J Clin Endocrinol Metab*, 84:3642-3647.
- Zitzmann, M. et al. 2002. Contraceptive steroids influence the hemostatic activation state in healthy men. *J Androl*, 23:503-511.